Richard Duke

ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.

MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO.

The Colorado Institute For Drug Device & Diagnostic Development provides health maintenance services. The American company was founded by Richard C. Duke.

Sierra Neuropharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of centrally-administered, small molecule therapeutics for the treatment of severe central nervous systems diseases refractory to oral medications. These include epilepsy, schizophrenia, bipolar disorder, anxiety disorders and major depression. The company uses a proprietary drug development process to reformulate pharmaceuticals for direct delivery to the brain via standard implantable pumps. The company was founded in 2005 and is headquartered in Aurora, CO.

PeptiVir, Inc. operates as a biopharmaceutical company focused on the development and commercialization of a conformationally-constrained, synthetic peptide-based vaccine platform for the prevention of viral diseases. The company is headquartered in Aurora, CO.